-- Work in Progress --
Please download the PDF program here

December 3rd 2014
Opening Ceremony **
Chair: Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo

17:00 Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo: Welcome and introduction
17:30 Giorgio Parmiani:
Award lecture of Fondazione Melanoma: Melanoma vaccines: New targets and combination therapy
18:00 Paul Lorigan: Clinical trial and real world evidence

Patients meet the melanoma experts **
Chair: Francesco De Lorenzo, Alessandro Testori

18:30 Francesco De Lorenzo, European Cancer Patient Coalition, ECPC: A pan-European policy strategy to overcome inequalities: Impact on Melanoma

Valerie Guild, AIM at Melanoma: The Challenges Ahead for Patient Advocacy

Bettina Ryll, Melanoma Patient Network Europe: Patient-centered clinical research in Melanoma

Representatives of Fondazione Melanoma Onlus Antonio Brancaccio, Elisabetta Colangelo

December 4th 2014
Molecular and Immuno advances
Chair: Gerardo Botti, Ena Wang

09:30 Boris C. Bastian: Genetic evolution of melanocytic neoplasia
09:55 Michael Davies: The multi-faceted roles of the PI3K-AKT pathway in melanoma
10:20 Roger Lo: Evolution of resistance to MAPK-targeted therapies
10:45 Gennaro Ciliberto: ErbB3 as a key factor in the development of resistance to RAF/MEK inhibitors in BRAF mutated melanoma
11:10 Break
11:25 Martin Mihm: Tumor Infiltrating Lymphocytes (TIL’s) Rule in Melanoma Prognosis
11:50 Alistair Cochran: Molecular enhancement of sentinel node evaluation
12:15 Sandra Demaria: Mechanisms of synergy of radiotherapy and immunotherapy
12:40 Discussion on the best abstracts submitted on Molecular and Immuno advances Gerardo Botti, Ena Wang

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells (Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, Giulia Mesiano, Michela Cangemi, Alessandro Zaccagna, Alberto Pisacane, Susanna Gallo, Fabrizio Carnevale-Schianca, Massimo Aglietta, Dario Sangiolo)

RSK1 activation promotes invasion in nodular melanoma (Amel Salhi, Joshua A. Farhadian, Keith M. Giles, Eleazar Vega-Saenz de Miera, Ines P. Silva, Caitlin Bourque, Karen Yeh, Sagar Chhangawala, Jinhua Wang, Fei Ye, David Y.Zhang, Eva Hernando, Yariv Houvras, Iman Osman)
13:30 Lunch and Poster Session
11:30 - 13:30 Sala Capuana
Launch of the Patients and Clinicians Italian Working Group on Melanoma**

Paolo A. Ascierto,
Antonio Brancaccio
Alberto Cerreti
Elisabetta Colangelo
Francesco De Lorenzo
Valerie Guild
Nicola Mozzillo
Chiara Puri Purini
Paola Queirolo
Carlo Riccardo Rossi
Alessandro Testori
Sara Vigna

Combination Therapies
Chair: Paolo A. Ascierto, Giuseppe Palmieri

14:30 Michael Atkins: Beyond BRAFi/MEKi: Combination and sequecing approaches for patients with BRAF mutant melanoma
14:55 Grant McArthur: Novel combination therapies for BRAF-mutant melanoma
15:20 Jeff Sosman: MEK + CDK4 a regimen for non-BRAF V6000 melanoma
15:45 Igor Puzanov: Combining targeted drugs and immunotherapy for melanoma
16:10 Break
16:25 Mario Sznol: Combination therapies based on PD-1/PDL-1 pathway antagonists
16:50 Samir Khleif: Strategies and designs for combination immune therapy
17:15 Silvia Formenti: Combining radiation therapy with immunotherapy: clinical translation
17:40 Nicola Mozzillo: Surgery in the combination therapies era
18:05 Discussion on the best abstracts submitted on Combination Therapies Paolo A. Ascierto, Giuseppe Palmieri

Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma (Adil Daud, Kathryn Toshimi Takamura, Tu Diep, Richard Heller, Robert H. Pierce)

coBRIM: A Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation–Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT01689519) (Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Ilsung Chang, Stephen P. Hack, Antoni Ribas)
18:35 Closing remarks and summing up for the next day, Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo

December 5th 2014
News in Immunotherapy
Chair: Claus Garbe, Alessandro Testori

09:20 John Kirkwood: Adjuvant therapy of melanoma in 2014
09:45 Soldano Ferrone: Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma
10:10 Rolf Kiessling: Myeloid derived suppressor cells in malignant melanoma are inhibitors of adaptive and innate immunity
10:35 Hassane M. Zarour: Targeting multiple inhibitory receptors to reverse melanoma-induced T cell dysfunction
11:00 Break
11:20 Barbara Seliger: Role of signal transduction and microRNAs on the immunogenicity of melanoma cells
11:45 David Stroncek: Advances in adoptive cellular therapy of cancer
12:10 Discussion on the best abstracts submitted on News in immunotherapy Claus Garbe, Alessandro Testori

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (Reinhard Dummer, Adil Daud, Igor Puzanov, Omid Hamid, Dirk Schadendorf, Caroline Robert, Jacob Schachter, Anna Pavlick, Rene Gonzalez, F. Stephen Hodi, Lee D. Cranmer, Christian Blank, Steven J. O’Day, Paolo A. Ascierto, April K.S. Salama, Nicole Xiaoyun Li, Wei Zhou, Joy Lis, Scot Ebbinghaus, S. Peter Kang, Antoni Ribas)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (Georgina V Long, Victoria Atkinson, Paolo A Ascierto, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Kerry J. Savage, Micaela Hernberg, Celeste Lebbé, Julie Charles, Catalin Mihalcioiu, Vanna Chiarion-Sileni, Cornelia Mauch, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, Christine Horak, Brian Sharkey, Ian M. Waxman, Caroline Robert)

Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients (Yago Pico de Coaña, Maria Wolodarski, Giusy Gentilcore, Yuya Yoshimoto, Isabel Poschke, Johan Hansson, Giuseppe V. Masucci, Rolf Kiessling)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients (Rossana Tallerico, Costanza M. Cristiani, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Ester Simeone, Andrea Dominijanni, Antonio M. Grimaldi, Francesco Colucci, Paolo A. Ascierto, Ennio Carbone)
13:20 Lunch and Poster Session

Tumor Microenvironment and Biomakers
Chair:Giuseppe Masucci, Magdalena Thurin

14:30 Reinard Dummer: Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
14:55 Sara Tomei: The immune-related role of BRAF in melanoma
15:20 Pedro Romero: T cell responses to melanoma antigens
15:45 Ignacio Melero: Molecular and cellular basis for immunomodulation with monoclonal antibodies
16:10 Break
16:25 Janis Taube: PD-LS and PD-1 as predictive markers of response to anti-PD-1
16:50 Thomas F. Gajewski: Re-activation of T cells within the tumor microenvironment
17:15 Bastian Schilling: Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
17:40 Discussion on the best abstracts submitted on Tumor Microenvironment and Biomarkers Giuseppe Masucci, Magdalena Thurin

Tumor-infiltrating lymphocytes predict cutaneous melanoma survival (Cristina Fortes, Simona Mastroeni, Thomas Manooranparanpampil, Francesca Passarelli, Alba Zappalà, Claudia Marino, Nicoletta Russo, Paola Michelozzi)

aß-Double Negative CD4/CD8 (CD56) T cell (DNTs) as prognostic markers in metastatic melanoma patients treated with Ipilimumab: preliminary evaluations (Giacoma De Tullio, Sabino Strippoli, Rosa Angarano, Vincenza De Fazio, Nicola Sgherza, Antonio Negri, Anna Albano, Pasquale Iacopino, Attilio Guarini, Michele Guida)

Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100) (Adil Daud, Alain Algazi, Michelle Ashworth, Michael Buljan, Kathryn Toshimi Takamura, Tu Diep, Robert H Pierce, Shailender Bhatia)
18:30 Closing remarks and summing up for the next day Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo

December 6th 2014
World-Wide Immunoscore Task Force: an Update**
Chair: Paolo A. Ascierto, Jerome Galon, Francesco M. Marincola

08:30 Immunoscore participants round table on recent advances

Jerome Galon: The Worldwide Immunoscore consortium in the era of tumor immunotherapies

Paolo A. Ascierto: Immunoscore in melanoma

Carlo Bifulco: SITC Immunoscore cloud hosting and an update on the Portland cohort

Ralf Huss: Quantitative Pathology for the discovery of immuno-oncological biomarkers

Magdalena Thurin: Immunoscore and immunoprofiling in clinical trials

Alessandro Lugli: The implementation of the immunoscore in the daily diagnostic practice of colorectal cancer: the pathologist’s point of view

Giuseppe Masucci: The contribution of Karolinska Institute to the immunoscore task force

Shahinaz Bedri: Qatar Immunoscore update-Breast Cancer Immunoscore Pilot Project

10:30 Discussion: Boris C. Bastian, Gerardo Botti, Sandra Demaria, Reinard Dummer, Thomas F. Gajewski, Martin Mihm, Janis Taube, Magdalena Thurin
11:15 Break

Regulatory Session
Chair: Paolo A. Ascierto, Pier Luigi Canonico

11:30 - 13:30 Roundtable on the economic sustainability of the new melanoma treatments: regulatory and market access issues
11:30 Alessandro Testori: Melanoma: the development of a multiprofessional discussion
11:45 Raj Puri: Regulatory Updates for Cancer Vaccines, Cellular and Gene Therapy Products
12:00 Francesco Pignatti
12:15 Paolo Foggi*
12:30 Paul Lorigan: Expanded Access Program and Compassionate Use
12:45 Claudio Jommi: Economic evaluation of new drugs and its role in managing their market access
13:00 Discussion: Francesco De Lorenzo, Teresita Mazzei, Francesco Rossi
13:30 CME Test

*To be confirmed
**Not included in the CME accredited program




For information please contact info@melanomabridge.org